Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of cevostamab + pomalidomide + dexamethasone versus standard therapy in relapsed/refractory multiple myeloma
CTR20262687Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cevostamab, pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by Roche. Started Jun 2026; status: active.
02
Drugs
cevostamabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20262687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262687.